



## Neos Therapeutics to Present at Two Upcoming September Conferences

August 29, 2019

DALLAS and FORT WORTH, Texas, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and manufacture central nervous system (CNS)-focused products, today announced that Jerry McLaughlin, Chief Executive Officer, will present a company overview at two upcoming conferences in September:

- 2019 Wells Fargo Healthcare Conference on Thursday, September 5, 2019 at 9:45 a.m. EDT in Boston, MA; and
- 21<sup>st</sup> Annual Global Investment Conference Sponsored by H.C. Wainwright on Tuesday, September 10, 2019 at 3:00 p.m. EDT in New York, NY.

Both presentations will be webcast live on the Investor Relations page of the Company's website at <http://investors.neostx.com/>. Following each presentation, a replay of the webcast will be available on Neos' website for 30 days.

### About Neos Therapeutics

Neos Therapeutics, Inc. (Nasdaq: NEOS) is a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and manufacture central nervous system (CNS)-focused products. The Company has three approved products, all for the treatment of ADHD, that utilize the Company's extended-release technology platform: Adzenys XR-ODT<sup>®</sup> (amphetamine) extended-release orally disintegrating tablets (see [Full Prescribing Information](#), including Boxed WARNING), Cotempla XR-ODT<sup>®</sup> (methylphenidate) extended-release orally disintegrating tablets (see [Full Prescribing Information](#), including Boxed WARNING), and Adzenys-ER<sup>®</sup> (amphetamine) extended-release oral suspension (see [Full Prescribing Information](#), including Boxed WARNING). Additional information about Neos is available at [www.neostx.com](http://www.neostx.com).

### CONTACTS:

Richard I. Eisenstadt  
Chief Financial Officer  
Neos Therapeutics  
(972) 408-1389  
[reisenstadt@neostx.com](mailto:reisenstadt@neostx.com)

Sarah McCabe  
Investor Relations  
Stern Investor Relations, Inc.  
(212) 362-1200  
[sarah.mccabe@sternir.com](mailto:sarah.mccabe@sternir.com)



Source: Neos Therapeutics, Inc.